Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia.
作者信息
Gonzaga Yung, Sanches Jose A
机构信息
National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil; Grupo Oncoclínicas, Rio de Janeiro, RJ, Brazil.
University of Sao Paulo Medical School, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2025 May 17;47(3):103844. doi: 10.1016/j.htct.2025.103844.
Abstract
摘要
相似文献
1
Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia.
Hematol Transfus Cell Ther. 2025 May 17;47(3):103844. doi: 10.1016/j.htct.2025.103844.
2
Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer.
Cochrane Database Syst Rev. 2022 Nov 28;11(11):CD013604. doi: 10.1002/14651858.CD013604.pub2.
3
Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH.
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S346-S361. doi: 10.1016/j.htct.2024.11.119. Epub 2024 Dec 18.
4
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Eur J Cancer. 2006 Oct;42(15):2433-53. doi: 10.1016/j.ejca.2006.05.002. Epub 2006 Jun 5.
5
Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD004139. doi: 10.1002/14651858.CD004139.pub2.
6
Reducing inappropriate antibiotic use in febrile neutropenia in hematology patients through the implementation of an antibiotic de-escalation protocol.
Infect Control Hosp Epidemiol. 2025 May 16;46(7):1-6. doi: 10.1017/ice.2025.90.
7
Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer.
Lancet Child Adolesc Health. 2022 Apr;6(4):260-268. doi: 10.1016/S2352-4642(21)00337-0. Epub 2021 Dec 3.
8
Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Medicine (Baltimore). 2010 Sep;89(5):308-318. doi: 10.1097/MD.0b013e3181f2caef.
9
Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
Cochrane Database Syst Rev. 2014 Oct 30;2014(10):CD003039. doi: 10.1002/14651858.CD003039.pub2.
10
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
Cochrane Database Syst Rev. 2016 Apr 24;4(4):CD006247. doi: 10.1002/14651858.CD006247.pub3.
本文引用的文献
1
Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH.
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S346-S361. doi: 10.1016/j.htct.2024.11.119. Epub 2024 Dec 18.
2
Causes of Death in Cutaneous T-Cell Lymphoma Patients.
Dermatology. 2023;239(6):860-867. doi: 10.1159/000531979. Epub 2023 Aug 23.
3
Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0174421. doi: 10.1128/AAC.01744-21. Epub 2021 Nov 29.
4
Shock and Early Death in Hematologic Patients with Febrile Neutropenia.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01250-19. Print 2019 Nov.
5
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.
Clin Infect Dis. 2020 Mar 3;70(6):1068-1074. doi: 10.1093/cid/ciz319.
6
Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.
Br J Dermatol. 2018 Dec;179(6):1322-1328. doi: 10.1111/bjd.17073. Epub 2018 Oct 12.
7
Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.
Cochrane Database Syst Rev. 2017 Jun 3;6(6):CD003914. doi: 10.1002/14651858.CD003914.pub4.
8
Risk Factors for Skin Infections in Mycosis Fungoides.
Dermatology. 2016;232(6):731-737. doi: 10.1159/000455944. Epub 2017 Mar 2.
9
Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.
Br J Dermatol. 2008 Jul;159(1):105-12. doi: 10.1111/j.1365-2133.2008.08612.x. Epub 2008 Jul 1.
10
Infections complicating mycosis fungoides and Sézary syndrome.
JAMA. 1992 Mar 11;267(10):1354-8.
Zotero 插件